Annual banned-substance review

Annual banned-substance review: analytical approaches in human sports drug testing

Corresponding Author

Mario Thevis

Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany

European Monitoring Center for Emerging Doping Agents, Cologne, Germany

Correspondence to: Mario Thevis, Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany. E-mail: [email protected]; [email protected]Search for more papers by this author

Tiia Kuuranne,

Tiia Kuuranne

Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Genève and Lausanne, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Epalinges, Switzerland

Search for more papers by this author

Hans Geyer,

Hans Geyer

Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany

European Monitoring Center for Emerging Doping Agents, Cologne, Germany

Search for more papers by this author

Wilhelm Schänzer,

Wilhelm Schänzer

Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany

Search for more papers by this author

Mario Thevis,

Corresponding Author

Mario Thevis

Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany

European Monitoring Center for Emerging Doping Agents, Cologne, Germany

Tiia Kuuranne,

Tiia Kuuranne

Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Genève and Lausanne, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Epalinges, Switzerland

Search for more papers by this author

Hans Geyer,

Hans Geyer

Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany

European Monitoring Center for Emerging Doping Agents, Cologne, Germany

Search for more papers by this author

Wilhelm Schänzer,

Wilhelm Schänzer

Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany

Search for more papers by this author

First published: 25 November 2016

https://doi.org/10.1002/dta.2139

Citations: 16

Share a link

Email
Facebook
x
LinkedIn
Reddit
Wechat

Abstract

There has been an immense amount of visibility of doping issues on the international stage over the past 12 months with the complexity of doping controls reiterated on various occasions. Hence, analytical test methods continuously being updated, expanded, and improved to provide specific, sensitive, and comprehensive test results in line with the World Anti-Doping Agency's (WADA) 2016 Prohibited List represent one of several critical cornerstones of doping controls. This enterprise necessitates expediting the (combined) exploitation of newly generated information on novel and/or superior target analytes for sports drug testing assays, drug elimination profiles, alternative test matrices, and recent advances in instrumental developments. This paper is a continuation of the series of annual banned-substance reviews appraising the literature published between October 2015 and September 2016 concerning human sports drug testing in the context of WADA's 2016 Prohibited List. Copyright © 2016 John Wiley & Sons, Ltd.

References

1 Commentary. Dope rules. Nature. 2015, 527, 276.
10.1038/527276a
CASPubMedWeb of Science®Google Scholar
2E. R. Eichner. News and Views on Russian Doping, Spin Rhabdo, and Renal Stones. Curr. Sports Med. Rep. 2016, 15, 2.
10.1249/JSR.0000000000000228
PubMedWeb of Science®Google Scholar
3D. Gerrard. Drug misuse in sport: a historical perspective. N. Z. Med. J. 2015, 128, 16.
PubMedWeb of Science®Google Scholar
4E. Liepinsh, M. Dambrova. The unusual pharmacokinetics of meldonium: Implications for doping. Pharmacol. Res. 2016, 111, 100.
10.1016/j.phrs.2016.05.029
CASPubMedWeb of Science®Google Scholar
5 World Anti-Doping Agency. Notice - Meldonium. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/2016-06-30-meldonium_notice.pdf [9 September 2016].
Google Scholar
6D. K. Chan, N. Ntoumanis, D. F. Gucciardi, R. J. Donovan, J. A. Dimmock, S. J. Hardcastle, M. S. Hagger. What if it really was an accident? The psychology of unintentional doping. Br. J. Sports Med. 2016, 50, 898.
10.1111/medu.13117
PubMedWeb of Science®Google Scholar
7H.-J. Helmlin, A. Mürner, S. Steiner, M. Kamber, C. Weber, H. Geyer, S. Guddat, W. Schänzer, M. Thevis. Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination. Forensic Sci. Int. 2016, 267, 166.
10.1016/j.forsciint.2016.08.029
CASPubMedWeb of Science®Google Scholar
8S. Devi. Overhaul of global anti-doping system needed. Lancet. 2016, 387, 2188.
10.1016/S0140-6736(16)30662-6
PubMedWeb of Science®Google Scholar
9A. C. Smith, B. Stewart. Why the war on drugs in sport will never be won. Harm Reduct. J. 2015, 12, 53.
10.1186/s12954-015-0087-5
PubMedWeb of Science®Google Scholar
10J. Mazanov. Beyond antidoping and harm minimisation: a stakeholder-corporate social responsibility approach to drug control for sport. J. Med. Ethics. 2016, 42, 220.
10.1136/medethics-2015-102661
PubMedWeb of Science®Google Scholar
11M. Hämäläinen. How to restore fairness after doping infringement? Bioethics. 2016.
10.1111/bioe.12265
PubMedWeb of Science®Google Scholar
12A. Curtis, D. Gerrard, P. Burt, H. Osborne. Drug misuse in sport: a New Zealand perspective. N. Z. Med. J. 2015, 128, 62.
PubMedWeb of Science®Google Scholar
13G. G. Wagner, N. R. Ziebarth. Inevitable? Doping attitudes among Berliners in 2011: the role of socialist state socialisation and athlete experience. Eur. J. Public Health. 2016, 26, 520.
10.1093/eurpub/ckw046
PubMedWeb of Science®Google Scholar
14D.K. Chan, R.J. Donovan, V. Lentillon-Kaestner, S.J. Hardcastle, J.A. Dimmock, D.A. Keatley, M.S. Hagger. Young athletes' awareness and monitoring of anti-doping in daily life: Does motivation matter? Scand. J. Med. Sci. Sports 2015, 25, e655.
10.1111/sms.12362
Web of Science®Google Scholar
15K. Till, B. Jones, J. McKenna, L. Whitaker, S. H. Backhouse. The search for size: a doping risk factor in adolescent rugby? Br. J. Sports Med. 2016, 50, 203.
10.1136/bjsports-2015-094737
PubMedWeb of Science®Google Scholar
16D. J. Madigan, J. Stoeber, L. Passfield. Perfectionism and attitudes towards doping in junior athletes. J. Sports Sci. 2016, 34, 700.
10.1080/02640414.2015.1068441
PubMedWeb of Science®Google Scholar
17H. P. Dijkstra, N. van Dyk, Y. O. Schumacher. Can I tell you something?I'm doping. Br. J. Sports Med. 2016, 50, 510.
10.1136/bjsports-2015-095602
CASPubMedWeb of Science®Google Scholar
18J. W. Honour. Doping in sport: consequences for health, clinicians and laboratories. Ann. Clin. Biochem. 2016, 53, 189.
10.1177/0004563216631572
PubMedWeb of Science®Google Scholar
19S. E. Willick, G. D. Miller, D. Eichner. The anti-doping movement. PMR. 2016, 8, S125.
10.1016/j.pmrj.2015.12.001
PubMedWeb of Science®Google Scholar
20D. Hughes. The World Anti-Doping Code in sport: Update for 2015. Aust. Prescr. 2015, 38, 167.
10.18773/austprescr.2015.059
PubMedWeb of Science®Google Scholar
21T. Yamaguchi, I. Horio, M. Goto, Y. Miyauchi, F. Izushi. Clarification of the relationship between awareness of doping of competitive sports coaches and their instructions to prevent doping. Yakugaku Zasshi. 2016, 136, 1185.
10.1248/yakushi.15-00291
CASPubMedWeb of Science®Google Scholar
22K. Fitch. The World Anti-Doping Code: can you have asthma and still be an elite athlete? Breathe (Sheff). 2016, 12, 148.
10.1183/20734735.004116
PubMedWeb of Science®Google Scholar
23A. Eichner, T. Tygart. Adulterated dietary supplements threaten the health and sporting career of up-and-coming young athletes. Drug Test. Anal. 2016, 8, 304.
10.1002/dta.1899
CASPubMedWeb of Science®Google Scholar
24M. Thevis, T. Kuuranne, K. Walpurgis, H. Geyer, W. Schänzer. Annual banned-substance review: analytical approaches in human sports drug testing. Drug Test. Anal. 2016, 8, 7.
10.1002/dta.1928
CASPubMedWeb of Science®Google Scholar
25M. Thevis, H. Geyer, L. Tretzel, W. Schänzer. Sports drug testing using complementary matrices: Advantages and limitations. J. Pharm. Biomed. Anal. 2016.
10.1016/j.jpba.2016.03.055
Web of Science®Google Scholar
26 World Anti-Doping Agency. The 2016 Prohibited List. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/wada-2016-prohibited-list-en.pdf [4 January 2016].
Google Scholar
27 World Anti-Doping Agency. The 2016 Monitoring Program. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/wada-2016-monitoring-program-en.pdf [16 September 2016].
Google Scholar
28I. R. Hullstein, H. Malerod-Fjeld, Y. Dehnes, P. Hemmersbach. Black market products confiscated in Norway 2011-2014 compared to analytical findings in urine samples. Drug Test. Anal. 2015, 7, 1025.
10.1002/dta.1900
CASPubMedWeb of Science®Google Scholar
29C. Weber, M. Kamber, V. Lentillon-Kaestner, O. Krug, M. Thevis. Seizures of doping substances at the Swiss Border--a descriptive investigation. Forensic Sci. Int. 2015, 257, 359.
10.1016/j.forsciint.2015.10.001
CASPubMedWeb of Science®Google Scholar
30S. R. Bird, C. Goebel, L. M. Burke, R. F. Greaves. Doping in sport and exercise: anabolic, ergogenic, health and clinical issues. Ann. Clin. Biochem. 2016, 53, 196.
10.1177/0004563215609952
CASPubMedWeb of Science®Google Scholar
31M. Mazzarino, L. Cesarei, X. de la Torre, I. Fiacco, P. Robach, F. Botre. A multi-targeted liquid chromatography-mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes. J. Pharm. Biomed. Anal. 2016, 117, 47.
10.1016/j.jpba.2015.08.007
CASPubMedWeb of Science®Google Scholar
32M. Thevis, W. Schänzer. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs. Rapid Commun. Mass Spectrom. 2016, 30, 635.
10.1002/rcm.7470
CASPubMedWeb of Science®Google Scholar
33M. Papaloucas, K. Kyriazi, V. Kouloulias. Pheromones: a new ergogenic aid in sport? Int. J. Sports Physiol. Perform. 2015, 10, 939.
10.1123/ijspp.2014-0226
PubMedWeb of Science®Google Scholar
34R. Ventura, X. Matabosch, J. Segura. Bioanalytical techniques in discrimination between therapeutic and abusive use of drugs in sport. Bioanalysis. 2016, 8, 965.
10.4155/bio.15.253
CASPubMedWeb of Science®Google Scholar
35F. Ponzetto, S. Giraud, N. Leuenberger, J. Boccard, R. Nicoli, N. Baume, S. Rudaz, M. Saugy. Methods for doping detection. Front. Horm. Res. 2016, 47, 153.
10.1159/000445177
PubMedWeb of Science®Google Scholar
36W. Schänzer, M. Thevis. Human sports drug testing by mass spectrometry. Mass Spectrom. Rev. 2015.
PubMedWeb of Science®Google Scholar
37F. Botre, X. de la Torre, M. Mazzarino. Multianalyte LC-MS-based methods in doping control: what are the implications for doping athletes? Bioanalysis. 2016, 8, 1129.
10.4155/bio-2016-0083
CASPubMedWeb of Science®Google Scholar
38H. Schröter, B. Studzinski, P. Dietz, R. Ulrich, H. Striegel, P. Simon. A comparison of the cheater detection and the unrelated question models: a randomized response survey on physical and cognitive doping in recreational triathletes. PLoS One. 2016, 11e0155765.
10.1371/journal.pone.0155765
Web of Science®Google Scholar
39A. Petroczi, S. H. Backhouse, V. Barkoukis, R. Brand, A. M. Elbe, L. Lazuras, F. Lucidi. A call for policy guidance on psychometric testing in doping control in sport. Int. J. Drug Policy. 2015, 26, 1130.
10.1016/j.drugpo.2015.04.022
PubMedWeb of Science®Google Scholar
40D. A. Hood, L. D. Tryon, H. N. Carter, Y. Kim, C. C. Chen. Unravelling the mechanisms regulating muscle mitochondrial biogenesis. Biochem. J. 2016, 473, 2295.
10.1042/BCJ20160009
CASPubMedWeb of Science®Google Scholar
41P. A. Andreux, R. H. Houtkooper, J. Auwerx. Pharmacological approaches to restore mitochondrial function. Nat. Rev. Drug Discov. 2013, 12, 465.
10.1038/nrd4023
CASPubMedWeb of Science®Google Scholar
42M. Okada-Iwabu, M. Iwabu, K. Ueki, T. Yamauchi, T. Kadowaki. Perspective of small-molecule AdipoR agonist for Type 2 diabetes and short life in obesity. Diabetes Metab. J. 2015, 39, 363.
10.4093/dmj.2015.39.5.363
PubMedWeb of Science®Google Scholar
43J. Dib, A. Thomas, P. Delahaut, E. Fichant, W. Schanzer, M. Thevis. Identification and characterization of in vitro and in vivo generated metabolites of the adiponectin receptor agonists AdipoRon and 112254. J. Pharm. Biomed. Anal. 2016, 125, 68.
10.1016/j.jpba.2016.03.027
CASPubMedWeb of Science®Google Scholar
44R. Iyer, D. J. Handelsman. Androgens. Front. Horm. Res. 2016, 47, 82.
10.1159/000445159
PubMedWeb of Science®Google Scholar
45A. Borjesson, N. Garevik, M. L. Dahl, A. Rane, L. Ekstrom. Recruitment to doping and help-seeking behavior of eight female AAS users. Subst. Abuse Treat. Prev. Policy. 2016, 11, 11.
10.1186/s13011-016-0056-3
PubMedWeb of Science®Google Scholar
46J. R. Kovac, J. Scovell, R. Ramasamy, S. Rajanahally, R. M. Coward, R. P. Smith, L. I. Lipshultz. Men regret anabolic steroid use due to a lack of comprehension regarding the consequences on future fertility. Andrologia. 2015, 47, 872.
10.1111/and.12340
CASPubMedWeb of Science®Google Scholar
47K. Veras, F. L. Silva-Junior, A. E. Lima-Silva, F. R. De-Oliveira, F. O. Pires. Impaired physical performance and clinical responses after a recreational bodybuilder's self-administration of steroids: a case report. World J. Mens Health. 2015, 33, 209.
10.5534/wjmh.2015.33.3.209
PubMedWeb of Science®Google Scholar
48E. Cha, S. Kim, H. W. Kim, K. M. Lee, H. J. Kim, O. S. Kwon, J. Lee. Relationships between structure, ionization profile and sensitivity of exogenous anabolic steroids under electrospray ionization and analysis in human urine using liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 2016, 30, 555.
10.1002/bmc.3583
CASPubMedWeb of Science®Google Scholar
49S. Rzeppa, G. Heinrich, P. Hemmersbach. Analysis of anabolic androgenic steroids as sulfate conjugates using high performance liquid chromatography coupled to tandem mass spectrometry. Drug Test. Anal. 2015, 7, 1030.
10.1002/dta.1895
CASPubMedWeb of Science®Google Scholar
50 World Anti-Doping Agency. Minimum Required Performance Levels for Detection and Identification of Non-Threshold Substances. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/wada_td2015mrpl_minimum_required_perf_levels_en.pdf [28 September 2015].
Google Scholar
51A. Kotronoulas, J. Marcos, J. Segura, R. Ventura, J. Joglar, O. J. Pozo. Ultra high performance liquid chromatography tandem mass spectrometric detection of glucuronides resistant to enzymatic hydrolysis: Implications to doping control analysis. Anal. Chim. Acta. 2015, 895, 35.
10.1016/j.aca.2015.08.043
CASPubMedWeb of Science®Google Scholar
52E. D. Virus, B. P. Luzyanin, A. V. Ivanov, A. A. Kubatiev. High-temperature high-performance liquid chromatography on a porous graphitized carbon column coupled to an Orbitrap mass spectrometer with atmospheric pressure photoionization for screening exogenous anabolic steroids in human urine. Rapid Commun. Mass Spectrom. 2015, 29, 1779.
10.1002/rcm.7278
CASPubMedWeb of Science®Google Scholar
53 World Anti-Doping Agency. Minimum criteria for chromatographic-mass spectrometric confirmation of the identity of analytes for doping control purposes. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/wada_td2015idcr_minimum_criteria_chromato-mass_spectro_conf_en.pdf [8 July 2016].
Google Scholar
54L. Novakova, V. Desfontaine, F. Ponzetto, R. Nicoli, M. Saugy, J. L. Veuthey, D. Guillarme. Fast and sensitive supercritical fluid chromatography - tandem mass spectrometry multi-class screening method for the determination of doping agents in urine. Anal. Chim. Acta. 2016, 915, 102.
10.1016/j.aca.2016.02.010
CASPubMedWeb of Science®Google Scholar
55V. Desfontaine, L. Novakova, F. Ponzetto, R. Nicoli, M. Saugy, J. L. Veuthey, D. Guillarme. Liquid chromatography and supercritical fluid chromatography as alternative techniques to gas chromatography for the rapid screening of anabolic agents in urine. J. Chromatogr. A. 2016, 1451, 145.
10.1016/j.chroma.2016.05.004
CASPubMedWeb of Science®Google Scholar
56E. Cha, S. Kim, H. J. Kim, K. M. Lee, K. H. Kim, O. S. Kwon, J. Lee. Sensitivity of GC-EI/MS, GC-EI/MS/MS, LC-ESI/MS/MS, LC-Ag(+) CIS/MS/MS, and GC-ESI/MS/MS for analysis of anabolic steroids in doping control. Drug Test. Anal. 2015, 7, 1040.
10.1002/dta.1906
CASPubMedWeb of Science®Google Scholar
57Q. Dumont, M. Barcenas, H. Dossmann, I. Bailloux, C. Buisson, N. Mechin, A. Molina, F. Lasne, N. S. Rannulu, R. B. Cole. Improved steroids detection and evidence for their regiospecific decompositions using anion attachment mass spectrometry. Anal. Chem. 2016, 88, 3585.
10.1021/acs.analchem.5b04097
CASPubMedWeb of Science®Google Scholar
58M. Raro, T. Portoles, E. Pitarch, J. V. Sancho, F. Hernandez, L. Garrostas, J. Marcos, R. Ventura, J. Segura, O. J. Pozo. Potential of atmospheric pressure chemical ionization source in gas chromatography tandem mass spectrometry for the screening of urinary exogenous androgenic anabolic steroids. Anal. Chim. Acta. 2016, 906, 128.
10.1016/j.aca.2015.11.041
CASPubMedWeb of Science®Google Scholar
59M. Polet, W. Van Gansbeke, P. Van Eenoo, K. Deventer. Efficient approach for the detection and identification of new androgenic metabolites by applying SRM GC-CI-MS/MS: a methandienone case study. J. Mass Spectrom. 2016, 51, 524.
10.1002/jms.3781
CASPubMedWeb of Science®Google Scholar
60M. Polet, W. Van Gansbeke, P. Van Eenoo, K. Deventer. Gas chromatography/chemical ionization triple quadrupole mass spectrometry analysis of anabolic steroids: ionization and collision-induced dissociation behavior. Rapid Commun. Mass Spectrom. 2016, 30, 511.
10.1002/rcm.7472
CASPubMedWeb of Science®Google Scholar
61T. Piper, W. Schänzer, M. Thevis. Revisiting the metabolism of 19-nortestosterone using isotope ratio and high resolution/high accuracy mass spectrometry. J. Steroid Biochem. Mol. Biol. 2016, 162, 80.
10.1016/j.jsbmb.2015.12.013
CASPubMedWeb of Science®Google Scholar
62S. Rzeppa, L. Viet. Analysis of sulfate metabolites of the doping agents oxandrolone and danazol using high performance liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2016, 1029-1030, 1.
10.1016/j.jchromb.2016.06.028
CASPubMedWeb of Science®Google Scholar
63G. Balcells, O. J. Pozo, L. Garrostas, A. Esquivel, X. Matabosch, A. Kotronoulas, J. Joglar, R. Ventura. Detection and characterization of clostebol sulfate metabolites in Caucasian population. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2016, 1022, 54.
10.1016/j.jchromb.2016.03.028
CASPubMedWeb of Science®Google Scholar
64G. He, S. Yang, J. Lu, Y. Xu. New long term metabolite in human urine for metenolone misuse by liquid chromatography quadrupole time-of-flight mass spectrometry. Steroids. 2016, 105, 1.
10.1016/j.steroids.2015.10.015
CASPubMedWeb of Science®Google Scholar
65Y. Liu, J. Lu, S. Yang, Q. Zhang, Y. Xu. New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry and their application for doping control. Steroids. 2016, 108, 61.
10.1016/j.steroids.2016.01.013
CASPubMedWeb of Science®Google Scholar
66M. Okano, M. Sato, A. Kojima, S. Kageyama. Determination of mepitiostane metabolites in human urine by liquid chromatography/tandem mass spectrometry for sports drug testing. J. Pharm. Biomed. Anal. 2015, 115, 236.
10.1016/j.jpba.2015.07.016
CASPubMedWeb of Science®Google Scholar
67L. Geldof, E. Tudela, L. Lootens, J. van Lysebeth, P. Meuleman, G. Leroux-Roels, P. van Eenoo, K. Deventer. In vitro and in vivo metabolism studies of dimethazine. Biomed. Chromatogr. 2016, 30, 1202.
10.1002/bmc.3668
CASPubMedWeb of Science®Google Scholar
68S. Yang, J. Lu, Y. Xu, X. Wang. New oxymesterone metabolites in human by gas chromatography-tandem mass spectrometry and their application for doping control. Drug Test. Anal. 2016, 8, 633.
10.1002/dta.1836
CASPubMedWeb of Science®Google Scholar
69E. Palonek, M. Ericsson, N. Garevik, A. Rane, M. Lehtihet, L. Ekstrom. Atypical excretion profile and GC/C/IRMS findings may last for nine months after a single dose of nandrolone decanoate. Steroids. 2016, 108, 105.
10.1016/j.steroids.2016.02.004
CASPubMedWeb of Science®Google Scholar
70 World Anti-Doping Agency. Decision Limits for the Confirmatory Quantification of Threshold Substances. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/WADA-TD2014DL-v1-Decision-Limits-for-the-Quantification-of-Threshold-Substances-EN.pdf [23 October 2013].
Google Scholar
71M. Thevis, J. Dib, A. Thomas, S. Höppner, A. Lagojda, D. Kuehne, M. Sander, G. Opfermann, W. Schänzer. Complementing the characterization of in vivo generated N-glucuronic acid conjugates of stanozolol by collision cross section computation and analysis. Drug Test. Anal. 2015, 7, 1050.
10.1002/dta.1907
CASPubMedWeb of Science®Google Scholar
72L. Schiffer, S. Brixius-Anderko, F. Hannemann, J. Zapp, J. Neunzig, M. Thevis, R. Bernhardt. Metabolism of oral turinabol by human steroid hormone-synthesizing cytochrome P450 enzymes. Drug Metab. Dispos. 2016, 44, 227.
10.1124/dmd.115.066829
CASPubMedWeb of Science®Google Scholar
73F. Jeanneret, D. Tonoli, M. F. Rossier, M. Saugy, J. Boccard, S. Rudaz. Evaluation of steroidomics by liquid chromatography hyphenated to mass spectrometry as a powerful analytical strategy for measuring human steroid perturbations. J. Chromatogr. A. 2016, 1430, 97.
10.1016/j.chroma.2015.07.008
CASPubMedWeb of Science®Google Scholar
74N. Baume, H. Geyer, M. Vouillamoz, R. Grisdale, M. Earl, R. Aguilera, D. A. Cowan, M. Ericsson, G. Gmeiner, D. Kwiatkowska, N. Kioukia-Fougia, A. Molina, J. Ruivo, J. Segura, P. Van Eenoo, N. Jan, N. Robinson, M. Saugy. Evaluation of longitudinal steroid profiles from male football players in UEFA competitions between 2008 and 2013. Drug Test. Anal. 2016, 8, 603.
10.1002/dta.1851
CASPubMedWeb of Science®Google Scholar
75E. Strahm, J. E. Mullen, N. Garevik, M. Ericsson, J. J. Schulze, A. Rane, L. Ekstrom. Dose-dependent testosterone sensitivity of the steroidal passport and GC-C-IRMS analysis in relation to the UGT2B17 deletion polymorphism. Drug Test. Anal. 2015, 7, 1063.
10.1002/dta.1841
CASPubMedWeb of Science®Google Scholar
76P. Martin-Escudero, J. Munoz-Guerra, N. Del Prado, M. Galindo Canales, M. Fuentes Ferrer, S. Vargas, A. B. Soldevilla, E. Serrano-Garde, F. Miguel-Tobal, M. Maestro de Las Casas, C. Fernandez-Perez. Impact of UGT2B17 gene deletion on the steroid profile of an athlete. Physiol. Rep. 2015, 3.
Web of Science®Google Scholar
77E. Alladio, R. Caruso, E. Gerace, E. Amante, A. Salomone, M. Vincenti. Application of multivariate statistics to the Steroidal Module of the Athlete Biological Passport: A proof of concept study. Anal. Chim. Acta. 2016, 922, 19.
10.1016/j.aca.2016.03.051
CASPubMedWeb of Science®Google Scholar
78A. Fabregat, J. Marcos, J. Segura, R. Ventura, O. J. Pozo. Factors affecting urinary excretion of testosterone metabolites conjugated with cysteine. Drug Test. Anal. 2016, 8, 110.
10.1002/dta.1801
CASPubMedWeb of Science®Google Scholar
79F. Ponzetto, F. Mehl, J. Boccard, N. Baume, S. Rudaz, M. Saugy, R. Nicoli. Longitudinal monitoring of endogenous steroids in human serum by UHPLC-MS/MS as a tool to detect testosterone abuse in sports. Anal. Bioanal. Chem. 2016, 408, 705.
10.1007/s00216-015-9185-1
CASPubMedWeb of Science®Google Scholar
80G. Forsdahl, D. Erceg, T. Geisendorfer, M. Turkalj, D. Plavec, M. Thevis, L. Tretzel, G. Gmeiner. Detection of testosterone esters in blood. Drug Test. Anal. 2015, 7, 983.
10.1002/dta.1914
CASPubMedWeb of Science®Google Scholar
81O. Salamin, L. Jaggi, N. Baume, N. Robinson, M. Saugy, N. Leuenberger. Circulating microRNA-122 as potential biomarker for detection of testosterone abuse. PLoS One. 2016, 11e0155248.
10.1371/journal.pone.0155248
PubMedWeb of Science®Google Scholar
82K. Bailey, T. Yazdi, U. Masharani, B. Tyrrell, A. Butch, F. Schaufele. Advantages and limitations of androgen receptor-based methods for detecting anabolic androgenic steroid abuse as performance enhancing drugs. PLoS One. 2016, 11e0151860.
10.1371/journal.pone.0151860
Web of Science®Google Scholar
83N. Sculthorpe, L. Taylor, F. M. Grace. Prolonged androgenic anabolic steroid (AAS) induced QT interval shortening: a suitable screening tool? Drug Test. Anal. 2016, 8, 120.
10.1002/dta.1826
CASPubMedWeb of Science®Google Scholar
84A. Lagojda, D. Kuehne, O. Krug, A. Thomas, T. Wigger, U. Karst, W. Schänzer, M. Thevis. Identification of selected in vitro-generated phase-I metabolites of the steroidal selective androgen receptor modulator MK‑0773 for doping control purposes. Eur. J. Mass. Spectrom. 2016, 22, 49.
10.1255/ejms.1415
CASPubMedWeb of Science®Google Scholar
85C. C. Coss, A. Jones, J. T. Dalton. Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Invest. New Drugs. 2016, 34, 458.
10.1007/s10637-016-0353-8
CASPubMedWeb of Science®Google Scholar
86 World Anti-Doping Agency. 2014 Anti-Doping Testing Figures. Availabel at: https://wada-main-prod.s3.amazonaws.com/wada_2014_anti-doping-testing-figures_full-report_en.pdf [25 September 2015].
Google Scholar
87W. Jelkmann. Erythropoietin. Front. Horm. Res. 2016, 47, 115.
10.1159/000445174
CASPubMedWeb of Science®Google Scholar
88S. Annaheim, M. Jacob, A. Krafft, C. Breymann, M. Rehm, U. Boutellier. RhEPO improves time to exhaustion by non-hematopoietic factors in humans. Eur. J. Appl. Physiol. 2016, 116, 623.
10.1007/s00421-015-3322-6
CASPubMedWeb of Science®Google Scholar
89 World Anti-Doping Agency. WADA Technical Document for Sport Specific Analysis. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/wada-tdssa-v2.2-en.pdf [12 October 2015].
Google Scholar
90P. Reihlen, M. Blobel, R. Kempkes, C. Reichel, E. Volker Schanzer, B. Majer, W. Schanzer. Optimizing SAR-PAGE. Drug Test. Anal. 2015, 7, 1014.
10.1002/dta.1915
CASPubMedWeb of Science®Google Scholar
91P. Postnikov, G. Krotov, N. Mesonzhnik, Y. Efimova, G. Rodchenkov. Fc-fragment removal allows the EPO-Fc fusion protein to be detected in blood samples by IEF-PAGE. Drug Test. Anal. 2015, 7, 999.
10.1002/dta.1916
CASPubMedWeb of Science®Google Scholar
92J. Durussel, D. W. Haile, K. Mooses, E. Daskalaki, W. Beattie, M. Mooses, W. Mekonen, N. Ongaro, E. Anjila, R. K. Patel, N. Padmanabhan, M. W. McBride, J. D. McClure, Y. P. Pitsiladis. Blood transcriptional signature of recombinant human erythropoietin administration and implications for antidoping strategies. Physiol. Genomics. 2016, 48, 202.
10.1152/physiolgenomics.00108.2015
CASPubMedWeb of Science®Google Scholar
93R. Provenzano, A. Besarab, C. H. Sun, S. A. Diamond, J. H. Durham, J. L. Cangiano, J. R. Aiello, J. E. Novak, T. Lee, R. Leong, B. K. Roberts, K. G. Saikali, S. Hemmerich, L. A. Szczech, K. H. Yu, T. B. Neff. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin. J. Am. Soc. Nephrol. 2016, 11, 982.
10.2215/CJN.06890615
CASPubMedWeb of Science®Google Scholar
94R. A. Brigandi, B. Johnson, C. Oei, M. Westerman, G. Olbina, J. de Zoysa, S. D. Roger, M. Sahay, N. Cross, L. McMahon, V. Guptha, E. A. Smolyarchuk, N. Singh, S. F. Russ, S. Kumar, P. H. I. Investigators. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: A 28-day, phase 2A randomized trial. Am. J. Kidney Dis. 2016, 67, 861.
10.1053/j.ajkd.2015.11.021
CASPubMedWeb of Science®Google Scholar
95P. E. Pergola, B. S. Spinowitz, C. S. Hartman, B. J. Maroni, V. H. Haase. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016, 90, 1115.
10.1016/j.kint.2016.07.019
CASPubMedWeb of Science®Google Scholar
96C. Buisson, A. Marchand, I. Bailloux, A. Lahaussois, L. Martin, A. Molina. Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case. J. Pharm. Biomed. Anal. 2016, 121, 181.
10.1016/j.jpba.2016.01.029
CASPubMedWeb of Science®Google Scholar
97M. Thevis, S. Milosovich, H. Licea-Perez, D. Knecht, T. Cavalier, W. Schanzer. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls. Drug Test. Anal. 2016, 8, 858.
10.1002/dta.1870
CASPubMedWeb of Science®Google Scholar
98M. Thevis, O. Krug, T. Piper, H. Geyer, W. Schänzer. Solutions advertised as erythropoiesis-stimulating products were found to contain undeclared cobalt and nickel species. Int. J. Sports Med. 2016, 37, 82.
10.1055/s-0035-1569350
CASPubMedWeb of Science®Google Scholar
99E. N. Ho, G. H. Chan, T. S. Wan, P. Curl, C. M. Riggs, M. J. Hurley, D. Sykes. Controlling the misuse of cobalt in horses. Drug Test. Anal. 2015, 7, 21.
10.1002/dta.1719
CASPubMedWeb of Science®Google Scholar
100M. Thevis, M. Machnik, I. Schenk, O. Krug, T. Piper, W. Schänzer, M. Düe, U. Bondesson, M. Hedeland. Nickel in equine sports drug testing - pilot study results on urinary nickel concentrations. Rapid Commun. Mass Spectrom. 2016, 30, 982.
10.1002/rcm.7528
CASPubMedWeb of Science®Google Scholar
101C. Stoppe, J. Ney, M. Brenke, A. Goetzenich, C. Emontzpohl, G. Schalte, O. Grottke, M. Moeller, R. Rossaint, M. Coburn. Sub-anesthetic xenon increases erythropoietin levels in humans: a randomized controlled trial. Sports Med. 2016, 46, 1753.
10.1007/s40279-016-0505-1
PubMedWeb of Science®Google Scholar
102C. Tassel, B. Le Dare, I. Morel, T. Gicquel. Xenon: From rare gaz to doping product. Presse Med. 2016, 45, 422.
10.1016/j.lpm.2016.01.025
PubMedWeb of Science®Google Scholar
103A. R. Nicholls, R. I. Holt. Growth hormone and insulin-like growth factor-1. Front Horm Res. 2016, 47, 101.
10.1159/000445173
CASPubMedWeb of Science®Google Scholar
104P. Ferro, R. Ventura, C. Perez-Mana, M. Farre, J. Segura. Genetic and protein biomarkers in blood for the improved detection of GH abuse. J. Pharm. Biomed. Anal. 2016, 128, 111.
10.1016/j.jpba.2016.05.022
CASPubMedWeb of Science®Google Scholar
105I. van den Broek, M. Blokland, M. A. Nessen, S. Sterk. Current trends in mass spectrometry of peptides and proteins: Application to veterinary and sports-doping control. Mass Spectrom. Rev. 2015, 34, 571.
10.1002/mas.21419
CASPubMedWeb of Science®Google Scholar
106A. Thomas, C. Görgens, S. Guddat, D. Thieme, F. Dellanna, W. Schänzer, M. Thevis. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. J. Sep. Sci. 2016, 39, 333.
10.1002/jssc.201501060
CASPubMedWeb of Science®Google Scholar
107M. E. Meredith, T. S. Salameh, W. A. Banks. Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases. AAPS J. 2015, 17, 780.
10.1208/s12248-015-9719-7
CASPubMedWeb of Science®Google Scholar
108E. Semenistaya, I. Zvereva, A. Thomas, M. Thevis, G. Krotov, G. Rodchenkov. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin. Drug Test. Anal. 2015, 7, 919.
10.1002/dta.1787
CASPubMedWeb of Science®Google Scholar
109P. Ferro, R. Gutierrez-Gallego, J. Bosch, M. Farre, J. Segura. Fit-for-purpose radio receptor assay for the determination of growth hormone secretagogues in urine. J Biomol Screen. 2015, 20, 1268.
10.1177/1087057115594590
CASPubMedWeb of Science®Google Scholar
110A. Knoop, A. Thomas, E. Fichant, P. Delahaut, W. Schänzer, M. Thevis. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal. Bioanal. Chem. 2016, 408, 3145.
10.1007/s00216-016-9377-3
CASPubMedWeb of Science®Google Scholar
111A. Thomas, K. Walpurgis, L. Tretzel, P. Brinkkötter, E. Fichant, P. Delahaut, W. Schänzer, M. Thevis. Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS. Drug Test. Anal. 2015, 7, 990.
10.1002/dta.1868
CASPubMedWeb of Science®Google Scholar
112J. A. Janssen, L. J. Hofland, C. J. Strasburger, E. S. van den Dungen, M. Thevis. Potency of full-length MGF to induce maximal activation of the IGF-I R is similar to recombinant human IGF-I at high equimolar concentrations. PLoS One. 2016, 11e0150453.
10.1371/journal.pone.0150453
Web of Science®Google Scholar
113M. Couto, J. Stang, L. Horta, T. Stensrud, M. Severo, P. Mowinckel, D. Silva, L. Delgado, A. Moreira, K. H. Carlsen. Two distinct phenotypes of asthma in elite athletes identified by latent class analysis. J. Asthma. 2015, 52, 897.
10.3109/02770903.2015.1067321
PubMedWeb of Science®Google Scholar
114S. R. Del Giacco, D. Firinu, L. Bjermer, K. H. Carlsen. Exercise and asthma: an overview. Eur. Clin. Respir. J. 2015, 2, 27984.
10.3402/ecrj.v2.27984
PubMedWeb of Science®Google Scholar
115M. Hostrup, A. Kalsen, M. Auchenberg, J. Bangsbo, V. Backer. Effects of acute and 2-week administration of oral salbutamol on exercise performance and muscle strength in athletes. Scand. J. Med. Sci. Sports. 2016, 26, 8.
10.1111/sms.12298
CASPubMedWeb of Science®Google Scholar
116F. Pillard, M. Lavit, V. L. Cances, J. Rami, G. Houin, A. Didier, D. Riviere. Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes. Respir. Res. 2015, 16, 155.
10.1186/s12931-015-0315-2
PubMedWeb of Science®Google Scholar
117C. B. Haase, V. Backer, A. Kalsen, S. Rzeppa, P. Hemmersbach, M. Hostrup. The influence of exercise and dehydration on the urine concentrations of salbutamol after inhaled administration of 1600 microg salbutamol as a single dose in relation to doping analysis. Drug Test. Anal. 2016, 8, 613.
10.1002/dta.1828
CASPubMedWeb of Science®Google Scholar
118 World Anti-Doping Agency. The 2017 Prohibited List. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/2016-09-29_-_wada_prohibited_list_2017_eng_final.pdf [31 October 2016].
Google Scholar
119A. Dyreborg, N. Krogh, V. Backer, S. Rzeppa, P. Hemmersbach, M. Hostrup. Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men. Front. Pharmacol. 2016, 7, 150.
10.3389/fphar.2016.00150
PubMedWeb of Science®Google Scholar
120Z. Chundela, J. Grosse. Olodaterol and vilanterol detection in sport drug testing. Drug Test. Anal. 2015, 7, 980.
10.1002/dta.1918
CASPubMedWeb of Science®Google Scholar
121K. Walpurgis, A. Thomas, W. Schänzer, M. Thevis. Myostatin inhibitors in sports drug testing: Detection of myostatin-neutralizing antibodies in plasma/serum by affinity purification and western blotting. Proteomics Clin. Appl. 2016, 10, 195.
10.1002/prca.201500043
CASPubMedWeb of Science®Google Scholar
122N. Thanawala, S. Cheney, G. Wark, M. Thevis, A. Thomas, W. Madira, V. Tziaferi, J. Greening. Factitious administration of analogue insulin to a 2-year-old child. Br. J. Diabetes 2016, 16, 82.
10.15277/bjd.2016.080
Web of Science®Google Scholar
123A. Thomas, P. Brinkkötter, W. Schänzer, M. Thevis. Metabolism of human insulin after subcutaneous administration: A possible means to uncover insulin misuse. Anal. Chim. Acta. 2015, 897, 53.
10.1016/j.aca.2015.09.036
CASPubMedWeb of Science®Google Scholar
124A. Arduini, V. A. Zammit. A tennis lesson: sharp practice in the science behind the Sharapova case. Postgrad. Med. J. 2016, 92, 429.
10.1136/postgradmedj-2016-134124
PubMedWeb of Science®Google Scholar
125N. Hawkes. Sixty seconds on . . . meldonium. BMJ. 2016, 352, i1420.
10.1136/bmj.i1420
PubMedWeb of Science®Google Scholar
126M. Stuart, C. Schneider, K. Steinbach. Meldonium use by athletes at the Baku 2015 European Games. Br. J. Sports Med. 2016, 50, 694.
10.1136/bjsports-2015-095906
PubMedWeb of Science®Google Scholar
127C. Görgens, S. Guddat, J. Dib, H. Geyer, W. Schänzer, M. Thevis. Mildronate (Meldonium) in professional sports - monitoring doping control urine samples using hydrophilic interaction liquid chromatography - high resolution/high accuracy mass spectrometry. Drug Test. Anal. 2015, 7, 973.
10.1002/dta.1788
CASPubMedWeb of Science®Google Scholar
128L. Tretzel, C. Görgens, H. Geyer, A. Thomas, J. Dib, S. Guddat, V. Pop, W. Schänzer, M. Thevis. Analyses of Meldonium (Mildronate) from blood, dried blood spots (DBS), and urine suggest drug incorporation into erythrocytes. Int. J. Sports Med. 2016, 37, 500.
10.1055/s-0036-1582317
CASPubMedWeb of Science®Google Scholar
129M. Okano, M. Thevis, M. Sato, S. Kageyama. Analytical detection of trimetazidine produced by metabolic conversion of lomerizine in doping control analysis. Drug Test. Anal. 2016, 8, 869.
10.1002/dta.1893
CASPubMedWeb of Science®Google Scholar
130M. Okano, Y. Nishitani, M. Dohi, S. Kageyama. Effects of intravenous infusion of glycerol on blood parameters and urinary glycerol concentrations. Forensic Sci. Int. 2016, 262, 121.
10.1016/j.forsciint.2016.02.040
CASPubMedWeb of Science®Google Scholar
131Y. Dong, K. Yan, Y. Ma, Z. Yang, J. Zhao, J. Ding. A modified LC-MS/MS method to simultaneously quantify glycerol and mannitol concentrations in human urine for doping control purposes. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2016, 1022, 153.
10.1016/j.jchromb.2016.04.023
CASPubMedWeb of Science®Google Scholar
132V. F. Sardela, F. B. Scalco, K. M. Cavalcante, R. E. Simoni, D. R. Silva, H. M. Pereira, M. L. de Oliveira, F. R. Aquino Neto. Systematic analysis of glycerol: colourimetric screening and gas chromatography-mass spectrometric confirmation. Drug Test. Anal. 2015, 7, 967.
10.1002/dta.1823
CASPubMedWeb of Science®Google Scholar
133R. Abbott, D. E. Smith. The new designer drug wave: a clinical, toxicological, and legal analysis. J. Psychoactive Drugs. 2015, 47, 368.
10.1080/02791072.2015.1094591
PubMedWeb of Science®Google Scholar
134P. Adamowicz, J. Gieron, D. Gil, W. Lechowicz, A. Skulska, B. Tokarczyk. The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland. Drug Test. Anal. 2016, 8, 63.
10.1002/dta.1924
CASPubMedWeb of Science®Google Scholar
135F. P. Busardo, C. Kyriakou, S. Napoletano, E. Marinelli, S. Zaami. Mephedrone related fatalities: a review. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 3777.
CASPubMedWeb of Science®Google Scholar
136K. E. Friedl. U.S. Army Research on pharmacological enhancement of soldier performance: stimulants, anabolic hormones, and blood doping. J. Strength Cond. Res. 2015, 29, S71.
10.1519/JSC.0000000000001027
PubMedWeb of Science®Google Scholar
137I. Athanasiadou, P. Kiousi, N. Kioukia-Fougia, E. Lyris, Y. S. Angelis. Current status and recent advantages in derivatization procedures in human doping control. Bioanalysis. 2015, 7, 2537.
10.4155/bio.15.172
CASPubMedWeb of Science®Google Scholar
138B. D. Ahrens, Y. Kucherova, A. W. Butch. Detection of stimulants and narcotics by liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry for sports doping control. Methods Mol. Biol. 2016, 1383, 247.
10.1007/978-1-4939-3252-8_26
CASPubMedWeb of Science®Google Scholar
139J. Gutierrez-Hellin, J. J. Salinero, J. Abian-Vicen, F. Areces, B. Lara, C. Gallo, C. Puente, J. Del Coso. Acute consumption of p-synephrine does not enhance performance in sprint athletes. Appl. Physiol. Nutr. Metab. 2016, 41, 63.
10.1139/apnm-2015-0299
CASPubMedWeb of Science®Google Scholar
140G. Sigmund, J. Dib, L. Tretzel, T. Piper, C. Bosse, W. Schanzer, M. Thevis. Monitoring 2-phenylethanamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls. Drug Test. Anal. 2015, 7, 1057.
10.1002/dta.1909
CASPubMedWeb of Science®Google Scholar
141M. Wojtowicz, A. Jarek, K. Chajewska, E. Turek-Lepa, D. Kwiatkowska. Determination of designer doping agent - 2-ethylamino-1-phenylbutane - in dietary supplements and excretion study following single oral supplement dose. J. Pharm. Biomed. Anal. 2015, 115, 523.
10.1016/j.jpba.2015.07.025
CASPubMedWeb of Science®Google Scholar
142M. Wojtowicz, A. Jarek, K. Chajewska, D. Kwiatkowska. N,N-dimethyl-2-phenylpropan-1-amine quantification in urine: application to excretion study following single oral dietary supplement dose. Anal. Bioanal. Chem. 2016, 408, 5041.
10.1007/s00216-016-9609-6
CASPubMedWeb of Science®Google Scholar
143A. Kojima, Y. Nishitani, M. Sato, S. Kageyama, M. Dohi, M. Okano. Comparison of urine analysis and dried blood spot analysis for the detection of ephedrine and methylephedrine in doping control. Drug Test. Anal. 2016, 8, 189.
10.1002/dta.1803
CASPubMedWeb of Science®Google Scholar
144L. Mercolini, M. Protti, M. C. Catapano, J. Rudge, A. E. Sberna. LC-MS/MS and volumetric absorptive microsampling for quantitative bioanalysis of cathinone analogues in dried urine, plasma and oral fluid samples. J. Pharm. Biomed. Anal. 2016, 123, 186.
10.1016/j.jpba.2016.02.015
CASPubMedWeb of Science®Google Scholar
145T. Seif-Barghi, N. Moghadam, F. Kobarfard. Morphine/codeine ratio, a key in investigating a case of doping. Asian J. Sports Med. 2015, 6e28798.
10.5812/asjsm.28798
Google Scholar
146R. Verplaetse, J. Henion. Quantitative determination of opioids in whole blood using fully automated dried blood spot desorption coupled to on-line SPE-LC-MS/MS. Drug Test. Anal. 2016, 8, 30.
10.1002/dta.1927
CASPubMedWeb of Science®Google Scholar
147G. A. Gomez-Rios, N. Reyes-Garces, B. Bojko, J. Pawliszyn. Biocompatible solid-phase microextraction nanoelectrospray ionization: an unexploited tool in bioanalysis. Anal. Chem. 2016, 88, 1259.
10.1021/acs.analchem.5b03668
CASPubMedWeb of Science®Google Scholar
148X. de la Torre, D. Curcio, C. Colamonici, F. Molaioni, M. Cilia, F. Botre. Development and validation of a GC-C-IRMS method for the confirmation analysis of pseudo-endogenous glucocorticoids in doping control. Drug Test. Anal. 2015, 7, 1071.
10.1002/dta.1911
CASPubMedWeb of Science®Google Scholar
149J. O. Plumb, J. M. Otto, M. P. Grocott. 'Blood doping' from Armstrong to prehabilitation: manipulation of blood to improve performance in athletes and physiological reserve in patients. Extrem. Physiol. Med. 2016, 5, 5.
10.1186/s13728-016-0046-0
PubMedWeb of Science®Google Scholar
150C. B. Malm, N. S. Khoo, I. Granlund, E. Lindstedt, A. Hult. Autologous doping with cryopreserved red blood cells - effects on physical performance and detection by multivariate statistics. PLoS One. 2016, 11e0156157.
10.1371/journal.pone.0156157
Web of Science®Google Scholar
151A. Makhro, R. Huisjes, L. P. Verhagen, M. Manu-Pereira Mdel, E. Llaudet-Planas, P. Petkova-Kirova, J. Wang, H. Eichler, A. Bogdanova, R. van Wijk, J. L. Vives-Corrons, L. Kaestner. Red cell properties after different modes of blood transportation. Front Physiol. 2016, 7, 288.
10.3389/fphys.2016.00288
PubMedWeb of Science®Google Scholar
152N. Robinson, S. Giraud, Y. O. Schumacher, M. Saugy. Influence of transport and time on blood variables commonly measured for the athlete biological passport. Drug Test. Anal. 2016, 8, 199.
10.1002/dta.1804
CASPubMedWeb of Science®Google Scholar
153L. M. Lobigs, E. J. Knight, Y. O. Schumacher, C. J. Gore. Within-subject haemoglobin variation in elite athletes: a longitudinal investigation of 13 887 haemoglobin concentration readings. Drug Test. Anal. 2016, 8, 228.
10.1002/dta.1809
CASPubMedWeb of Science®Google Scholar
154J. Bejder, M. F. Hoffmann, M. Ashenden, N. B. Nordsborg, K. Karstoft, J. Morkeberg. Acute hyperhydration reduces athlete biological passport OFF-hr score. Scand. J. Med. Sci. Sports. 2016, 26, 338.
10.1111/sms.12438
CASPubMedWeb of Science®Google Scholar
155K. Alsaadi, S. C. Voss, S. Kraiem, A. Alwahaibi, S. Alyazedi, N. Dbes, R. Goebel, V. Mohamed-Ali, S. Alsowaidi, A. M. Seyam, A. S. Bashraheel, M. Alsayrafi, C. Georgakopoulos. The effect of fasting during Ramadan on parameters of the haematological and steroidal modules of the athletes biological passport - a pilot study. Drug Test. Anal. 2015, 7, 1017.
10.1002/dta.1917
CASPubMedWeb of Science®Google Scholar
156O. Salamin, S. De Angelis, J. D. Tissot, M. Saugy, N. Leuenberger. Autologous blood transfusion in sports: emerging biomarkers. Transfus. Med. Rev. 2016, 30, 109.
10.1016/j.tmrv.2016.05.007
PubMedWeb of Science®Google Scholar
157N. Leuenberger, L. Barras, R. Nicoli, N. Robinson, N. Baume, N. Lion, S. Barelli, J. D. Tissot, M. Saugy. Hepcidin as a new biomarker for detecting autologous blood transfusion. Am. J. Hematol. 2016, 91, 467.
10.1002/ajh.24313
CASPubMedWeb of Science®Google Scholar
158N. Leuenberger, L. Barras, R. Nicoli, N. Robinson, N. Baume, N. Lion, S. Barelli, J. D. Tissot, M. Saugy. Urinary di-(2-ethylhexyl) phthalate metabolites for detecting transfusion of autologous blood stored in plasticizer-free bags. Transfusion. 2016, 56, 571.
10.1111/trf.13408
CASPubMedWeb of Science®Google Scholar
159A. Stampella, S. Di Marco, D. Pirri, X. de la Torre, F. Botre, F. Donati. Application of DNA-based forensic analysis for the detection of homologous transfusion of whole blood and of red blood cell concentrates in doping control. Forensic Sci. Int. 2016, 265, 204.
10.1016/j.forsciint.2016.04.021
CASPubMedWeb of Science®Google Scholar
160N. Giuliani, M. Saugy, M. Augsburger, V. Varlet. Blood monitoring of perfluorocarbon compounds (F-tert-butylcyclohexane, perfluoromethyldecalin and perfluorodecalin) by headspace-gas chromatography-tandem mass spectrometry. Talanta. 2015, 144, 196.
10.1016/j.talanta.2015.05.015
CASPubMedWeb of Science®Google Scholar
161A. M. Elbe, S. N. Jensen, P. Elsborg, M. Wetzke, G. A. Woldemariam, B. Huppertz, R. Keller, A. W. Butch. The Urine Marker Test: An Alternative Approach to Supervised Urine Collection for Doping Control. Sports Med. 2016, 46, 15.
10.1007/s40279-015-0388-6
PubMedWeb of Science®Google Scholar
162L. Devesse, D. Syndercombe Court, D. Cowan. Determining the authenticity of athlete urine in doping control by DNA analysis. Drug Test. Anal. 2015, 7, 912.
10.1002/dta.1785
CASPubMedWeb of Science®Google Scholar
163Y. P. Pitsiladis, M. Tanaka, N. Eynon, C. Bouchard, K. N. North, A. G. Williams, M. Collins, C. N. Moran, S. L. Britton, N. Fuku, E. A. Ashley, V. Klissouras, A. Lucia, I. I. Ahmetov, E. de Geus, M. Alsayrafi, Athlome Project Consortium: a concerted effort to discover genomic and other "omic" markers of athletic performance. Physiol. Genomics. 2016, 48, 183.
10.1152/physiolgenomics.00105.2015
CASPubMedWeb of Science®Google Scholar
164G. Wang, M. Tanaka, N. Eynon, K. N. North, A. G. Williams, M. Collins, C. N. Moran, S. L. Britton, N. Fuku, E. A. Ashley, V. Klissouras, A. Lucia, I. I. Ahmetov, E. de Geus, M. Alsayrafi, Y. P. Pitsiladis. The future of genomic research in athletic performance and adaptation to training. Med. Sport Sci. 2016, 61, 55.
10.1159/000445241
PubMedGoogle Scholar
165E. W. Neuberger, I. Perez, C. Le Guiner, D. Moser, T. Ehlert, M. Allais, P. Moullier, P. Simon, R. O. Snyder. Establishment of two quantitative nested qPCR assays targeting the human EPO transgene. Gene Ther. 2016, 23, 330.
10.1038/gt.2016.2
CASPubMedWeb of Science®Google Scholar

Citing Literature

Volume9, Issue1

January 2017

Pages 6-29

Annual banned-substance review: analytical approaches in human sports drug testing

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Annual banned-substance review: analytical approaches in human sports drug testing

Abstract

References

Citing Literature

References

Related

Information